Search

Charles River Laboratories International Inc

Fermé

SecteurSoins de santé

218.49 -0.02

Résumé

Variation du prix de l'action

24h

Actuel

Min

211.86

Max

223.28

Chiffres clés

By Trading Economics

Revenu

262M

-15M

Ventes

1.6M

996M

BPA

2.06

Marge bénéficiaire

-1.486

Employés

18,300

EBITDA

-135M

64M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+4.92% upside

Dividendes

By Acuity

Prochains Résultats

5 août 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

2.1B

11B

Ouverture précédente

218.51

Clôture précédente

218.49

Sentiment de l'Actualité

By Acuity

100%

0%

323 / 340 Classement par Healthcare

Charles River Laboratories International Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 juil. 2026, 21:01 UTC

Charles River Laboratories shares moved lower in after-market trading, continuing a steady decline since Tuesday's close amid broader market concerns.

20 juil. 2026, 21:01 UTC

Shares of Charles River Laboratories International Inc are lower in after-market trading, continuing a trend of declines with no specific news to explain the movement.

Comparaison

Variation de prix

Charles River Laboratories International Inc prévision

Objectif de Prix

By TipRanks

4.92% hausse

Prévisions sur 12 Mois

Moyen 230.2 USD  4.92%

Haut 265 USD

Bas 213 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

10

Achat

2

Maintien

0

Vente

Sentiment

By Acuity

323 / 340Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat